What Is The Lawsuit About? The lawsuit has been filed on behalf of investors who purchased securities during the period of December 15, 2021 through September 16, 2025, inclusive ("the Class Period†). The lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants engaged in tax fraud; (2) Defendants committed bribery to cover up the fact that they committed tax fraud; and (3) as a result, defendants understated the leg ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until November 7, 2025 to ask the Court to appoint them as lead plaintiff. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened? On May ...

Core Viewpoint - Nutex Health Inc. is facing a class action lawsuit due to allegations of securities fraud related to its dealings with HaloMD, which reportedly engaged in fraudulent activities to benefit Nutex financially [3][5]. Group 1: Allegations and Impact - On July 22, 2025, a report by Blue Orca Capital claimed that HaloMD was involved in a fraudulent scheme that resulted in significant financial losses for insurance companies, leading to a decline in Nutex's share price by approximately 10.05% [3]. - Following Nutex's announcement on August 14, 2025, regarding a delay in filing its quarterly report due to accounting adjustments, the company's share price fell by about 16.39% [4]. Group 2: Details of the Lawsuit - The lawsuit covers investors who purchased Nutex securities from August 8, 2024, to August 14, 2025, alleging that Nutex made misleading statements and failed to disclose critical information regarding its financial practices and the sustainability of its revenue [5]. - Specific allegations include that Nutex overstated its financial health, mismanaged stock-based compensation obligations, and failed to adequately address weaknesses in its internal controls over financial reporting [5].

Sep 30, 2025 8:00 PM Eastern Daylight Time VFC INVESTORS: Kirby McInerney LLP Reminds V.F. Corporation Investors of Important Deadline in Class Action Lawsuit Share NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your V.F. Corporation ("VFC†or the "Company†) (NYSE:VFC) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Inves ...

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Firefly Aerospace for possible violations of federal securities laws or other unlawful business practices [1][3]. Financial Performance - On August 7, 2025, Firefly offered 19,296,000 shares at a public offering price of $45.00 per share [3]. - Firefly reported revenue of $15.5 million for its initial quarterly results, reflecting a year-over-year decline of over 27% [3]. - The company reported total operating expenses of $58.3 million, which is a year-over-year increase of more than 12% [3]. - Following the financial report, Firefly's share price dropped by $7.58, or approximately 15.31%, from $49.52 on September 22, 2025, to close at $41.94 on September 23, 2025 [3].

Core Viewpoint - Semler Scientific, Inc. is facing a class action lawsuit due to alleged securities fraud related to undisclosed investigations by the U.S. Department of Justice regarding the QuantaFlo device reimbursement claims [3][5]. Group 1: Company Background - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the DOJ dating back to July 2017 [3]. - The company has received multiple requests for information from the DOJ over the years, with the latest being in April 2023 [3]. Group 2: Financial Impact - Following the disclosure of the DOJ investigation, Semler's share price dropped by $4.03, approximately 9.39%, from $42.92 to $38.89 between February 28 and March 3, 2025 [3]. - After announcing a settlement agreement of $29.75 million on April 15, 2025, Semler's shares fell by $3.40, or about 9.9%, from $34.40 to $31.00 the following day [4]. Group 3: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Semler securities from March 10, 2021, to April 15, 2025, alleging that the company made false or misleading statements regarding the DOJ investigation [5]. - The lawsuit claims that the company failed to disclose material information about the investigation, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Savara Inc. is facing a class action lawsuit due to alleged securities fraud related to the FDA's refusal to file a Biologics License Application (BLA) for its product MOLBREEVI, which has led to a significant decline in share price [1][2][3]. Group 1: Lawsuit Details - The class action lawsuit is based on claims that Savara made false or misleading statements regarding the completeness of the MOLBREEVI BLA submission [3]. - The FDA's refusal to file letter indicated that the BLA was not sufficiently complete, particularly concerning Chemistry, Manufacturing, and Controls (CMC) [2][3]. - Following the announcement of the FDA's decision, Savara's share price dropped by $0.90, approximately 31.69%, from $2.84 to $1.94 [2]. Group 2: Investor Information - Investors who acquired Savara securities between March 7, 2024, and May 23, 2025, are urged to seek lead plaintiff appointment by the November 7, 2025 deadline [1]. - The law firm Kirby McInerney LLP is handling the case and encourages affected investors to contact them for more information [4][5].

Core Viewpoint - Semler Scientific, Inc. is facing a securities fraud class action lawsuit due to alleged misleading statements regarding a Department of Justice investigation into the company's reimbursement claims related to the QuantaFlo device [3][5]. Group 1: Company Background and Events - On February 28, 2025, Semler disclosed in its Form 10-K that it received a civil investigative demand from the DOJ in July 2017 concerning its reimbursement claims [3]. - Following unsuccessful settlement discussions with the DOJ in February 2025, Semler's share price fell by approximately 9.39%, from $42.92 to $38.89 [3]. - On April 15, 2025, Semler announced a settlement agreement of $29.75 million to resolve all claims, leading to a further decline in share price by about 9.9%, from $34.40 to $31.00 [4]. Group 2: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Semler securities from March 10, 2021, to April 15, 2025, alleging that the company made false or misleading statements regarding the DOJ investigation [5]. - The lawsuit claims that the company failed to disclose material information about the investigation, which resulted in investor damages when the truth was revealed [5].

Core Points - RCI Hospitality Holdings, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices [1] - New York's Office of the Attorney General indicted certain top executives of RCI, alleging bribery of an auditor to avoid over $8 million in sales taxes from 2010 to 2024 [3] - Following the indictment news, RCI's share price dropped by $5.53, approximately 16.11%, from $34.32 to $28.79 [3] Company Overview - RCI Hospitality Holdings, Inc. trades on NASDAQ under the ticker RICK [1] - The company is facing serious legal challenges that could impact its financial standing and reputation [1][3] Legal Context - The investigation is being conducted by Kirby McInerney LLP, a law firm specializing in securities litigation [1][6] - The firm has a history of recovering billions of dollars for shareholders in similar cases [6]

Core Viewpoint - Savara Inc. is facing a securities fraud class action lawsuit following a significant decline in its stock price after the FDA issued a refusal to file letter for its MOLBREEVI BLA therapy [3][4]. Group 1: Company Overview - Savara Inc. (NASDAQ:SVRA) is involved in the development of therapies, specifically the MOLBREEVI BLA intended for treating patients with aPap [3]. - The company experienced a stock price drop of approximately 31.69%, from $2.84 on May 23, 2025, to $1.94 on May 27, 2025, after the FDA's announcement [3]. Group 2: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Savara securities between March 7, 2024, and May 23, 2025 [4]. - Allegations in the lawsuit include that Savara made false or misleading statements regarding the completeness of the MOLBREEVI BLA submission and the likelihood of FDA approval [4]. - The lawsuit claims that the company failed to disclose the need for additional data related to Chemistry, Manufacturing, and Controls (CMC), which impacted the approval timeline and raised concerns about the need for additional capital [4].